Development of a brain metastatic canine prostate cancer cell line

Prostate. 2011 Sep;71(12):1251-63. doi: 10.1002/pros.21341. Epub 2011 Feb 14.

Abstract

Background: Prostate cancer in men has a high mortality and morbidity due to metastatic disease. The pathobiology of prostate cancer metastasis is not well understood and cell lines and animal models that recapitulate the complex nature of the disease are needed. Therefore, the goal of the study was to establish and characterize a new prostate cancer line derived from a dog with spontaneous prostate cancer.

Methods: A new cell line (Leo) was derived from a dog with spontaneous prostate cancer. Immunohistochemistry and PCR were used to characterize the primary prostate cancer and xenografts in nude mice. Subcutaneous tumor growth and metastases in nude mice were evaluated by bioluminescent imaging, radiography and histopathology. In vitro chemosensitivity of Leo cells to therapeutic agents was measured.

Results: Leo cells expressed the secretory epithelial cytokeratins (CK)8, 18, and ductal cell marker, CK7. The cell line grew in vitro (over 75 passages) and was tumorigenic in the subcutis of nude mice. Following intracardiac injection, Leo cells metastasized to the brain, spinal cord, bone, and adrenal gland. The incidence of metastases was greatest to the central nervous system (80%) with a lower incidence to bone (20%) and the adrenal glands (16%). In vitro chemosensitivity assays demonstrated that Leo cells were sensitive to Velcade and an HDAC-42 inhibitor with IC(50) concentrations of 1.9 nm and 0.95 µm, respectively.

Conclusion: The new prostate cancer cell line (Leo) will be a valuable model to investigate the mechanisms of the brain and bone metastases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Gland Neoplasms / epidemiology
  • Adrenal Gland Neoplasms / secondary
  • Animals
  • Antineoplastic Agents / pharmacology
  • Bone Neoplasms / epidemiology
  • Bone Neoplasms / secondary
  • Boronic Acids / pharmacology
  • Bortezomib
  • Brain Neoplasms / epidemiology
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / pathology*
  • Brain Neoplasms / secondary*
  • Carcinogenicity Tests
  • Carcinoma / epidemiology
  • Carcinoma / metabolism
  • Carcinoma / pathology*
  • Carcinoma / secondary*
  • Cell Division
  • Cell Line, Tumor* / drug effects
  • Cell Line, Tumor* / pathology
  • Dogs
  • Immunohistochemistry
  • Incidence
  • Injections, Subcutaneous
  • Keratin-18 / metabolism
  • Keratin-7 / metabolism
  • Keratin-8 / metabolism
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Neoplasms, Connective Tissue / secondary
  • Parathyroid Hormone-Related Protein / metabolism
  • Phenylbutyrates / antagonists & inhibitors
  • Prostatic Neoplasms / pathology*
  • Pyrazines / pharmacology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Spinal Cord Neoplasms / epidemiology
  • Spinal Cord Neoplasms / secondary
  • Subcutaneous Tissue
  • Transplantation, Heterologous

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • HDAC-42
  • Keratin-18
  • Keratin-7
  • Keratin-8
  • Parathyroid Hormone-Related Protein
  • Phenylbutyrates
  • Pyrazines
  • Bortezomib